1Grudmann H, Barwolff S, Tami A, et al. How many infections are caused by patient to patient transmission in intensive care units [J]. Crit Care Med,2005,33(6):946 -951.
2Mathews PJ,Mathews ML Reducing the risks of venilator-associated infections[J]. Dimens Crit Care Nurs, 2000,19 (8) : 17- 21.
5Farr BM, Bartlett CLR, Wadsworth J, et al. Risk factors for community acquired pneumonia diagnosed upon hospital admission [J]. Respir Med,2000,94(10) :954- 963.
6Farr BM,Woodhead MA, MacFarlane JT,et al. Risk factors for com- munity acquired pneumonia diagnosed by general practitioners in the community[J]. Respir Med, 2000,94 (5):422-427.
4Magiorakos AP, Srinivasan A,Garey RB, et al. Multidrug-resisi tant extensively drug-resistant and pandrug-resisitant bacteria,an international expert proposal for interim standard definitions for acquired residtance[J]. Clin Microb Infect, 2012,18(3) 268-281.
5Durante ME,Signoriello G,Andini R,et al. Colistin and rifampicin compared with colistin alone for the treatment of serious inec- tions due to extensively drug-resistant Aeinetobacter baumanniia multicentre, randomised, clinical trial[J]. Clin Infect Dis, 2013,57 (3) :349-358.
6Vincent. Microbial resistance lessons from the EPIC study[J]. In- tens Care Med,2000,26(1) :1301-1308.
7Vargas M, Horcajada JP. Clinical consequences of infection in pa- tients with acute strokeis it prime time for further antibiotic tri- als[J]. Stroke,2006,37(2) ..461-465.
8Hu WS,Yao SM,Fung CP, et al. An OXA-66/OXA-51-Like car- bapenemase and possibly an efflux pump are associated with re- sistance to imipenem in Acinetobacter bautmannii[J]. Antimierob Agents Chemother, 2007,51 (11) .. 3844-3852.
